[go: up one dir, main page]

SI3038654T1 - Nova uporaba - Google Patents

Nova uporaba

Info

Publication number
SI3038654T1
SI3038654T1 SI201431464T SI201431464T SI3038654T1 SI 3038654 T1 SI3038654 T1 SI 3038654T1 SI 201431464 T SI201431464 T SI 201431464T SI 201431464 T SI201431464 T SI 201431464T SI 3038654 T1 SI3038654 T1 SI 3038654T1
Authority
SI
Slovenia
Prior art keywords
new use
new
Prior art date
Application number
SI201431464T
Other languages
English (en)
Inventor
Victor Chengwei Shi
Martin Lefkowitz
Adel Remond Rizkala
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51494327&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3038654(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2013/056680 external-priority patent/WO2015030711A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SI3038654T1 publication Critical patent/SI3038654T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
SI201431464T 2013-08-26 2014-08-26 Nova uporaba SI3038654T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/US2013/056680 WO2015030711A1 (en) 2013-08-26 2013-08-26 New use
US201461972933P 2014-03-31 2014-03-31
PCT/IB2014/064074 WO2015028941A1 (en) 2013-08-26 2014-08-26 New use
EP14761702.1A EP3038654B1 (en) 2013-08-26 2014-08-26 New use

Publications (1)

Publication Number Publication Date
SI3038654T1 true SI3038654T1 (sl) 2020-02-28

Family

ID=51494327

Family Applications (3)

Application Number Title Priority Date Filing Date
SI201432059T SI3626270T1 (sl) 2013-08-26 2014-08-26 Zdravljenje srčno-žilnih bolezni
SI201431464T SI3038654T1 (sl) 2013-08-26 2014-08-26 Nova uporaba
SI201432099T SI4321157T1 (sl) 2013-08-26 2014-08-26 Nova uporaba kombinacije blokatorja receptorja angiotenzina (arb) z nevtralnim zaviralcem endopeptidaze (nepi)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201432059T SI3626270T1 (sl) 2013-08-26 2014-08-26 Zdravljenje srčno-žilnih bolezni

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201432099T SI4321157T1 (sl) 2013-08-26 2014-08-26 Nova uporaba kombinacije blokatorja receptorja angiotenzina (arb) z nevtralnim zaviralcem endopeptidaze (nepi)

Country Status (16)

Country Link
US (2) US20160213646A1 (sl)
EP (4) EP3626270B1 (sl)
JP (1) JP6097888B2 (sl)
CY (1) CY1122531T1 (sl)
DK (3) DK3626270T3 (sl)
ES (3) ES2767084T3 (sl)
FI (2) FI4321157T3 (sl)
HR (3) HRP20241763T1 (sl)
HU (3) HUE047186T2 (sl)
LT (3) LT3626270T (sl)
PL (3) PL4321157T3 (sl)
PT (3) PT4321157T (sl)
RS (3) RS59816B1 (sl)
SI (3) SI3626270T1 (sl)
SM (1) SMT202500001T1 (sl)
WO (1) WO2015028941A1 (sl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015028941A1 (en) 2013-08-26 2015-03-05 Novartis Ag New use
EP3253740A1 (en) * 2015-02-06 2017-12-13 Mylan Laboratories Ltd. Amorphous trisodium sacubitril valsartan and a process for the preparation thereof
EP3302460A1 (en) * 2015-05-29 2018-04-11 Novartis AG Sacubitril and valsartan for treating metabolic disease
CN106309388A (zh) * 2015-06-30 2017-01-11 深圳信立泰药业股份有限公司 一种用于心衰治疗的药物组合物及其制备方法
CN106491600A (zh) * 2015-09-06 2017-03-15 常州方楠医药技术有限公司 无定型沙库区比、缬沙坦或其药学上可接受的盐与药用辅料的组合物及其制备方法
WO2017036420A1 (zh) * 2015-09-06 2017-03-09 常州方楠医药技术有限公司 含沙库比曲和缬沙坦的药用组合物及其制备方法
CN107510653A (zh) * 2016-06-17 2017-12-26 常州爱诺新睿医药技术有限公司 一种含有无定型沙库比曲和缬沙坦的固体分散体的药用组合物及其制备方法
WO2017042700A1 (en) * 2015-09-07 2017-03-16 Sun Pharmaceutical Industries Limited Solid forms of valsartan and sacubitril
CN106580908A (zh) * 2015-10-16 2017-04-26 深圳信立泰药业股份有限公司 一种用于心血管疾病治疗的口服制剂及其制备方法
CN105330609B (zh) * 2015-12-07 2017-12-22 南京正大天晴制药有限公司 一种制备lcz696的方法
EP4609912A3 (en) 2016-02-03 2025-11-12 Novartis AG New use of a combination of sacubitril and valsartan
CN106176681A (zh) * 2016-08-25 2016-12-07 泰力特医药（湖北）有限公司 一种抗心脏衰竭药物lcz696口服缓释微丸及其制备方法
US11382866B2 (en) 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
EP3840746A1 (en) * 2018-08-23 2021-06-30 Novartis AG New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
JP7316449B2 (ja) 2019-09-20 2023-07-27 シェンヅェン サルブリス ファーマシューティカルズ カンパニー リミテッド 心不全治療におけるアンジオテンシンｉｉ受容体アンタゴニスト代謝産物とｎｅｐ阻害剤との複合体の使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000050I1 (de) 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
CN1249682A (zh) * 1997-01-10 2000-04-05 麦克公司 用于治疗有症状的心力哀竭的血管紧张素ⅱ拮抗剂
RU2334513C3 (ru) * 2002-01-17 2017-10-24 Новартис Аг Фармацевтические композиции, включающие валсартан и ингибиторы нейтральной эндопептидазы (nep)
MXPA05012299A (es) * 2003-05-16 2006-01-30 Novartis Ag Composicion farmaceutica que comprende valsartan.
AR057882A1 (es) * 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
EP3067043B1 (en) 2007-11-06 2022-11-30 Novartis AG Pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor
RU2531948C2 (ru) 2008-11-22 2014-10-27 Дженентек, Инк. Антиангиогенная терапия, применяемая для лечения рака молочной железы
KR101864865B1 (ko) 2010-08-24 2018-06-05 노파르티스 아게 항응고제 요법을 받고 있는 포유동물에서의 고혈압의 치료 및／또는 심부전의 예방 또는 치료
JP6482462B2 (ja) 2012-08-24 2019-03-13 ノバルティス アーゲー 心房拡大又はリモデリングを特徴とする疾患を治療するためのｎｅｐ阻害剤
WO2015028941A1 (en) 2013-08-26 2015-03-05 Novartis Ag New use
US20160206597A1 (en) * 2013-08-26 2016-07-21 Toni Lynne Bransford New Use

Also Published As

Publication number Publication date
LT4321157T (lt) 2025-01-10
EP3038654A1 (en) 2016-07-06
PT3626270T (pt) 2024-01-11
EP3626270A1 (en) 2020-03-25
PL4321157T3 (pl) 2025-03-03
HUE064634T2 (hu) 2024-04-28
FI3626270T3 (fi) 2024-01-11
JP2016528303A (ja) 2016-09-15
JP6097888B2 (ja) 2017-03-15
EP3038654B1 (en) 2019-10-30
ES3001196T3 (es) 2025-03-04
SI3626270T1 (sl) 2024-03-29
EP4512397A2 (en) 2025-02-26
FI4321157T3 (fi) 2025-01-20
RS65037B1 (sr) 2024-02-29
LT3626270T (lt) 2024-01-25
PL3038654T3 (pl) 2020-05-18
HRP20240034T1 (hr) 2024-03-29
ES2968541T3 (es) 2024-05-10
LT3038654T (lt) 2020-01-27
RS66371B1 (sr) 2025-02-28
CY1122531T1 (el) 2021-01-27
ES2767084T3 (es) 2020-06-16
SMT202500001T1 (it) 2025-03-12
US20160213646A1 (en) 2016-07-28
EP4321157A2 (en) 2024-02-14
DK3626270T3 (da) 2024-01-15
PT4321157T (pt) 2025-01-08
HUE047186T2 (hu) 2020-04-28
WO2015028941A1 (en) 2015-03-05
SI4321157T1 (sl) 2025-03-31
EP4321157A3 (en) 2024-05-15
HRP20241763T1 (hr) 2025-03-14
RS59816B1 (sr) 2020-02-28
EP3626270B1 (en) 2023-10-11
HRP20200060T1 (hr) 2020-04-03
DK4321157T3 (da) 2024-12-16
DK3038654T3 (da) 2020-02-03
EP4512397A3 (en) 2025-05-14
EP4321157B1 (en) 2024-10-23
HUE069419T2 (hu) 2025-03-28
PT3038654T (pt) 2020-02-04
US20210077461A1 (en) 2021-03-18
PL3626270T3 (pl) 2024-04-08

Similar Documents

Publication Publication Date Title
FIC20240019I1 (fi) Fetsolinetantti
IL246002A0 (en) Novel methods
DK3342773T3 (da) Syk-hæmmere
DK3613453T3 (da) Fordamper
SI3038654T1 (sl) Nova uporaba
DK3077047T3 (da) Aramcholsalte
DK3052081T3 (da) Pastil
DK3060460T3 (da) Saddel
PT2961752T (pt) Imidazopiridazinas substituídas
DK3027598T3 (da) Oxoquinazolinyl-butanamidderivater
DK2956698T3 (da) Bindestrimler
DK2946640T3 (da) Langmuir-probe
EP2943489A4 (en) DEUTERATED MOMELOTINIB
DE102013106534B8 (de) Chromatographiepipettenspitze
EP2991647A4 (en) DEUTERED AMLEXANOX
EP2970310A4 (en) 5-BROMO-indirubins
EP2853297A4 (en) kendama
DK3071227T3 (da) Fiskevaccine
DE112014001252A5 (de) Aufbissschiene
PT3022200T (pt) Novos agentes antimaláricos
DK3086679T3 (da) Sportssko
DK2981168T3 (da) Laminitiskile
FI10138U1 (fi) Kelkkateltta
ES1078715Y (es) Mosquitera
DE112014005422A5 (de) Friktionsfalschdrallaggregat